



The NCI SBIR Program



About the Small Business Innovation Research Program (SBIR)



Established through the Small Business Innovation Development Act of 1982 with aims to:

- **Stimulate technological innovation**
- **Use small business to meet federal R&D needs**
- **Foster and encourage participation by minorities and disadvantaged persons in technological innovation**
- **Increase private-sector commercialization innovations derived from federal R&D**


- **Assemble the scientific and business expertise needed to optimally manage the SBIR program**
 - **Integrate all SBIR initiatives with NCI's program priorities**
 - **Foster collaborations with other Institutes at NIH which share common technology needs**
- ***Increase the return on investment for the SBIR program***

In FY 2007, NCI made a strategic shift toward funding more SBIR contracts in areas with greatest commercial potential

Point of Care Analysis for Circulating Tumor Cells (CTCs)

➤ **Project Goals**

- ❑ To develop Point of Care devices and methods of CTC detection, enumeration, isolation, removal and molecular analysis
- ❑ To provide tools with cost and/or performance advantages over current technologies



*A CTC detected using
ACD's RNAscope™*

Companion Diagnostics

➤ **Project Goals**

- ❑ To provide noninvasive tests to evaluate molecular profiles of patients
- ❑ To develop companion diagnostics to select patients for whom a particular therapeutic regimen will be safe and effective

Focused solicitations = ~24% of SBIR Budget

- **The National Cancer Institute high-priority research areas include, but are not limited to:**
 - Cancer Biology
 - Cancer Prevention
 - Cancer Therapeutics
 - E-Health and Software Development
 - Imaging Technologies
 - Interventional Devices
 - *In Vitro* and Companion Diagnostics
 - Nanotechnology
 - Proteomics
 - Radiation Therapy

Set Aside

- **SBIR:** Set-aside program for small business concerns to engage in Federal R&D with the potential for commercialization
- **STTR:** Set-aside program to facilitate cooperative R&D between small business concerns and U.S. research institutions with potential for commercialization

2.5%

0.3%

~\$110 million annually at the **NCI**

~\$650 million annually at the **NIH**


SBIR

- **Permits** research institution partners (e.g., universities)
- Small business concern may outsource ~33% of Phase I activities and 50% of Phase II activities

STTR


- **Requires** research institution partners (e.g., universities)
- Minimum 40% of the work should be conducted by the small business concern (for profit), and minimum of 30% by a U.S. research institution (non-profit)

Award always made to small business



PHASE I – R41, R43

- Feasibility Study
- \$150K and 6-month (SBIR) *
- *or* 12-month (STTR) Award



PHASE II – R42, R44

- Full Research/R&D
- \$1 million and 2-year Award (SBIR & STTR) *
- Commercialization plan required

Phase II Bridge Award



PHASE III

- Commercialization Stage
- Use of non-SBIR/STTR Funds

* Note: Actual funding levels may differ by topic.


Why are SBIR & STTR Important?



- **NCI's primary resource for enabling commercialization of innovative high impact technologies, such as:**
 - **Cancer Diagnostics**
 - **Cancer Imaging**
 - **Small Molecules and Biologics**
 - **Electronic Health & Education Tools**
- **Provides incentive to academic investigators to translate technology (new company formation)**
- **SBIR Program is one of the rare sources of seed funding for companies which is stable and predictable**


23 Different Institutes/Centers at NIH With SBIR Programs

Rank By Size 1-23



SBIR Portfolio Summary (Active as of July 1 2010)

Grants & Contracts -- \$110M budget



Phase I Awards:
246 (51%)

Phase II Awards:
234 (49%)

Grants:
355 (74%)

Contracts:
125 (24%)

(480 projects, Phase I & II, SBIR & STTR)

SBIR Development Center Staff



Michael Weingarten, MA (*Director*)

Previous

- **NASA** – Program Manager, NASA Technology Commercialization Program



Greg Evans, PhD (*Branch Chief*)

Previous

- **NHLBI/NIH** – Program Director, Translational and Multicenter Clinical Research in Hemoglobinopathies
- **NHGRI/NIH** – Senior Staff Fellow



Patti Weber, DrPH (*Program Director*)

Previous

- **International Heart Institute of Montana** – Tissue Engineering and Surgical Research
- **Ribi ImmunoChem Research, Inc.** – Team Leader, Cardiovascular Pharmacology



David Beylin, MS, MBA (*Program Director*)

Previous

- **X/Seed Capital Management, LLC**, Consultant
- **Naviscan PET Systems, Inc.**, Vice President, Research



Deepa Narayanan, MS (*Program Director*)

Previous

- **Naviscan PET Systems, Inc.**, Director, Clinical Data Management (Oncology Imaging & Clinical Trials)
- **Fox Chase Cancer Center**, Scientific Associate (Molecular Imaging Lab)



Jennifer Shieh, PhD (*AAAS Science & Technology Policy Fellow*)

Previous

- **National Academy of Sciences** – Christine Mirzayan Science and Technology Policy Fellow
- **Syapse, Inc.** – Biology Associate



Ali Andalibi, PhD (*Branch Chief*)

Previous

- **NSF** – SBIR Program Director, Medical Biotechnology
- **House Ear Institute** – Scientist & Director, New Technology and Project Development
- **Trega Biosciences, Inc.** – Research Scientist



Andrew J. Kurtz, PhD (*Branch Chief*)

Previous

- **NIH** – AAAS Science & Technology Policy Fellow
- **Cedra Corporation** – Research Associate, Bio-Analytical Assays and Pharmacokinetics Analysis



Jian Lou, PhD (*Program Director*)

Previous

- **Johnson & Johnson** – Research Scientist, Target Validation & Biomarker Development
- **Lumicyte, Inc.** – Director, Molecular Biology Systems Analysis



Todd Haim, PhD (*Program Manager*)

Previous

- **National Academy of Sciences** – Christine Mirzayan Science and Technology Policy Fellow
- **Pfizer Research Laboratories** – Postdoctoral Fellow, Cardiac Pathogenesis & Metabolic Disorders



Amir Rahbar, PhD, MBA (*Program Director*)

Previous

- **NCI** – Program Director, Center for Strategic Scientific Initiatives
- **Naval Research Laboratory** – Research Scientist



Julienne Willis (*Program Specialist*)

Michael Weingarten
Director
SBIR Development Center
Phone: 301-594-7709
weingartenm@mail.nih.gov

For more information on companies who have successfully leveraged SBIR funding, please visit:
<http://www.sbir.cancer.gov/success/>

Sign-up for funding and program updates
<http://sbir.cancer.gov>



Follow us on Twitter @ [NCIsbir](https://twitter.com/NCIsbir)